Skip directly to content

Hasty Passage of the Tax and Health Care Bill

Contact:
Suraj Madoori
TAG U.S. and Global Health Policy Director
917-530-5996
smadoori@treatmentactiongroup.org

With the hasty passage of the tax and health care bill passed along party lines yesterday afternoon, Congress has sent a clear message on how they prioritize communities living with and vulnerable to HIV, tuberculosis (TB), and hepatitis C virus (HCV) in the upcoming mid-term election year. The bill was signed on December 22, 2017 by the President, and it hands massive tax-cuts to corporations and the wealthy.

HCV Treatment Access in U.S. Prisons: Legal and Policy Challenges
October 2, 2017 - Treatment Access Group joined oined National Viral Hepatitis Roundtable and the Hepatitis Education Project to present this update on HCV DAA treatment access in the U.S. prison system.

HCV Global Access Webinars Archive
2015 - A series of two Webinars that offered the opportunity to engage with leading experts on cutting-edge issues in HCV treatment access advocacy.

 

Webinar: Hepatitis C Treatment Access in Prisons: Legal and Policy Challenges

On Monday, October 2, 2017, Treatment Access Group joined National Viral Hepatitis Roundtable and the Hepatitis Education Project to present this update on HCV DAA treatment access in the U.S. prison system. The webinar included information about newly available treatments, drug pricing in the prison system, key lawsuits, and legal tactics designed to expand access in correctional settings.

Speakers included:

  • Mandy Altman, MPA
    Correctional Health Program Manager, Hepatitis Education Project
  • Elizabeth Paukstis, MA, JD
    Public Policy Director, NVHR
  • Annette Gaudino
    HCV/HIV Project Co-Director,

Webinar: Exploring the Implications of the Delamanid Phase III and STREAM Trial Results

Note that the following PDFs listed at the top of this page were handouts shared with the Webinar:
--Phase III Clinical Trial Results at the 48th Union World Conference on Lung Health: Implications for the Field1, PDF
--TB CAB's Proposed Development Pathway for Regimens to Treat Extensively Drug-Resistant Tuberculosis, PDF
--The Devil We Know: Is the Use of Injectable Agents for the Treatment of MDR-TB Justified? PDF

               The Results Are In: Now What? Webinar Video

The first ever phase III trials for multidrug-resistant TB (MDR-TB) finally yielded results.

On December 13, 2017, TAG participated in a hearing in Geneva, Switzerland to brief members of the Human Rights Council on human rights concerns in the United Arab Emirates (UAE). The meeting was held in preparation for the UAE’s Universal Period Review (UPR), a mechanism by which the human rights record of each United Nations member state is reviewed by other countries every five years.  

Civil society organizations can submit information to the HRC and put forward recommendations for how the country under review can better respect its human rights obligations as established by the Universal

On October 12, 2017, in Guadalajara, Mexico, Treatment Action Group, Advanced Access & Delivery, Harvard Medical School, Partners In Health, and the Stop TB Partnership sponsored a symposium in conjunction with the Union World Conference on Lung Health.

Introduction - Erica Lessem (Treatment Action Group) and Eloisa "Louie" Zepeda-Teng (TB meningitis survivor, the Philippines)

 

Remarks - Dr. Lucica Ditiu (Stop TB Partnership)

 

Panel 1: Perceptions of Risk - Dr. Cesar Bonilla (formerly of National TB Program, Perú), Dr.  Aamir Khan (Interactive Research & Development, Pakistan), Dr.

HIV Cure Research Information Sheet

December 2017

HIV Cure Research Status: Quick Summary

  • One person, Timothy Ray Brown, is considered cured, and there are several other documented cases where HIV viral load did not rebound for an extended period after an ART interruption (referred to as remission)
  • These outcomes remain rare and resulted from exceptional circumstances—stem cell transplants for HIV-positive people with cancers or extremely early initiation of ART—but they are providing important clues to researchers working to develop a cure
  • There are more numerous—but still relatively rare—examples of individuals who have

NEWS ON THE FIGHT TO END HIV/AIDS, VIRAL HEPATITIS, AND TUBERCULOSIS

TAGline Fall 2017

EVERYBODY IN, NOBODY OUT

Arguments favoring universal health care (UHC) are easy. Achieving political consensus as to the best strategy to achieve this is considerably more vexing. This is particularly true in the U.S., where the Affordable Care Act (ACA) patchwork of legislation and regulations has faced a barrage of executive and legislative attacks since the beginning of the year. And although the ACA and expansion of Medicaid in 32 states represents the closest the U.S.

Fall 2017 TAGline

December 2017

EVERYBODY IN, NOBODY OUT
By Tim Horn

Arguments favoring universal health care (UHC) are easy. Achieving political consensus as to the best strategy to achieve this is considerably more vexing. This is particularly true in the U.S., where the Affordable Care Act (ACA) patchwork of legislation and regulations has faced a barrage of executive and legislative attacks since the beginning of the year. And although the ACA and expansion of Medicaid in 32 states represents the closest the U.S.

Pages